Boehringer Ingelheim's Nerandomilast Shows Potential Multi-Year Survival Benefit in IPF and PPF
Event summary
- Boehringer Ingelheim's nerandomilast demonstrated potential to extend median survival by up to 5.4 years in IPF and 3.3 years in PPF based on long-term survival modeling from FIBRONEER™ trials.
- Findings presented at ATS 2026 and EULAR 2026 congresses suggest nerandomilast could more than double median survival in IPF patients when used as monotherapy.
- Pooled analysis of FIBRONEER™ trials showed a 59% nominally significant reduction in the risk of death for nerandomilast 18 mg monotherapy compared to placebo.
- Nerandomilast is currently approved in the US, China, UAE, and Japan for IPF and PPF, with additional regulatory submissions under review in the EU, UK, and other countries.
The big picture
Boehringer Ingelheim's nerandomilast represents a significant advancement in the treatment of IPF and PPF, diseases with high mortality rates and limited therapeutic options. The potential survival benefits highlighted by the FIBRONEER™ trials could position nerandomilast as a key player in the pulmonary fibrosis market, particularly if regulatory approvals are secured in major markets. The focus on long-term survival modeling underscores the strategic importance of developing therapies that not only slow disease progression but also extend patients' lives.
What we're watching
- Regulatory Approvals
- Whether nerandomilast will secure additional regulatory approvals in the EU, UK, and other countries by the end of 2026, expanding its market reach.
- Clinical Validation
- The pace at which real-world evidence and data from the FIBRONEER™-ON open-label extension trials will confirm the long-term survival benefits predicted by the modeling.
- Market Competition
- How Boehringer Ingelheim will position nerandomilast against existing therapies in the IPF and PPF markets, particularly given its potential survival benefits.
Related topics